Evidence map›Paper›PMID 41047548›Full record

ArticleBritish journal of haematology2026

The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-X

Nahide Yildirim, Marius Anders, Victoria M Smith, Sandrine Jayne, Moritz Assmann, Rebekah Jukes-Jones, Martin J S Dyer, Meike Vogler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nahide YildirimInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Marius AndersInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Victoria M SmithThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Sandrine JayneThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Moritz AssmannInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
Rebekah Jukes-JonesThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.
Martin J S DyerThe Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0002-5033-2236
Meike VoglerInstitute for Experimental Pediatric Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.ORCID https://orcid.org/0000-0003-2650-586X

Funding

Deutsche KrebshilfeElse-Kröner Fresenius StiftungScott Waudby Charitable TrustWilhelm-Sander Stiftung
6 · The paper itself

Abstract

BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B-cell malignancies such as diffuse large B-Cell lymphoma (DLBCL) is complicated by the more heterogeneous nature of the disease. Successful responses are limited to a subset of patients, highlighting the need for robust biomarkers predicting sensitivity. Here, we investigated the underlying mechanisms of inherent resistance to the BCL2i ABT-199 and BCL-X

Indexed as

Apoptosisbcl-X ProteinLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2AnimalsAntineoplastic AgentsApoptosis Regulatory ProteinsBcl-2-Like Protein 11BenzothiazolesBridged Bicyclo Compounds, HeterocyclicCell Line, TumorDrug Resistance, NeoplasmHumansIsoquinolinesMicePeptide FragmentsA-1331852Antineoplastic AgentsApoptosis Regulatory ProteinsBCL2L1 protein, humanBcl-2-Like Protein 11BCL2 protein, humanbcl-X ProteinBenzothiazolesBridged Bicyclo Compounds, HeterocyclicIsoquinolinesPeptide FragmentsPMAIP1 protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2SulfonamidesvenetoclaxapoptosisBCL2 proteinsBH3‐mimeticsDLBCLvenetoclax

Identifiers

PMID41047548
PMCPMC12819106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.